|1.||Zent, Olaf: 3 articles (03/2009 - 04/2004)|
|2.||Wittermann, Christoph: 2 articles (03/2009 - 03/2009)|
|3.||Leonova, Galina N: 1 article (05/2009)|
|4.||Pavlenko, Elena V: 1 article (05/2009)|
|5.||Petri, Eckhardt: 1 article (03/2009)|
|6.||Schöndorf, I: 1 article (03/2009)|
|7.||Gniel, D: 1 article (03/2009)|
|8.||Jilg, Wolfgang: 1 article (02/2009)|
|9.||Kuhr, Hans B: 1 article (02/2009)|
|10.||Plentz, Annelie: 1 article (02/2009)|
|1.||Tick-Borne Encephalitis (Encephalitis, Tick Borne)
04/01/2004 - "Long-term immunity after vaccination against tick-borne encephalitis with Encepur using the rapid vaccination schedule."
06/12/2006 - "A prospective, randomised, multicentre, single-blind phase 3 study was performed to assess the safety of a vaccination schedule consisting of two vaccinations (21-35 days apart) with the tick-borne encephalitis (TBE) vaccine FSME-IMMUN "adults" (five consecutive lots) in comparison to another licensed TBE vaccine (Encepur), with polygeline) (two lots) in healthy volunteers (n=3966) aged 16-65 years. "
03/04/2009 - "Long-term persistence of tick-borne encephalitis antibodies in children 5 years after first booster vaccination with Encepur Children."
03/04/2009 - "Two paediatric tick-borne encephalitis vaccines, Encepur Children and FSME-IMMUN Junior, are used widely in Europe. "
02/05/2009 - "Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults."
05/11/2009 - "During the first year and 2 years after the primary three vaccinations the antibodies to the Far Eastern subtype tick-borne encephalitis virus strain P-73 were detected by neutralization test after immunization with FSME-Immune Inject vaccine (Baxter Vaccine AG, Austria) in 88.2% and 78.1% vaccinated persons, respectively; with Encepur((R)) Adult vaccine (Novartis Vaccines, Germany), in 100% and 100%; with the vaccine of the Chumakov Institute of Poliomyelitis and Viral Encephalitides RAMSci (Russia), in 100% and 94.1%; with EnceVir vaccine (Russia), in 88.2% and 83.9%; and after combined vaccination, in 100% and 92.7%. "